1Massin P, Audren F, Haouchine B,et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema:preliminary results of a prospective controlled trial. Ophthalmology, 2004, 11(1) :218-224.
2Shima C, Oqata N, Minamino K, et al. Posterior sub-Tenon injection of triamcinolone aeetonide as pretreatment for focal laser photoeoagulation in diabetic macular edema patients. Jpn J Ophthalmol, 2008,52 :265-268.
7Penfold PL, Gyory IF, Hunyor AB, et al. Exudative maculardegeneration and intravitreal triamcinolone: a pilot study[ J ]. Aust N Z Ophthalmol, 1995,23 : 293 - 298.
8GiUiies MC, Kuzniarz M, Craig J, et al. Intravitreal triam cinolone- induced elevated intraocular pressure is associated with the development of posterior subcapsuiar cataract[ J ]. Ophthalmology, 2005,112 : 139 - 143.
9Audren F, Tod M, Massion P, et al. Pharmacokinetic pharm acodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic rnacular edema[J]. Invest Ophthalmol Vis Sci, 2004, 45 : 3 435 - 3 441.
10Martidis A, Duker JS, Greenberg PB, et al. lntravitreal triameinolone for refractory diabetic rrmcular ederna[J ]. Ophthalmology, 2002,109(5) :920 - 927.
